SG11201810627UA - Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases - Google Patents

Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases

Info

Publication number
SG11201810627UA
SG11201810627UA SG11201810627UA SG11201810627UA SG11201810627UA SG 11201810627U A SG11201810627U A SG 11201810627UA SG 11201810627U A SG11201810627U A SG 11201810627UA SG 11201810627U A SG11201810627U A SG 11201810627UA SG 11201810627U A SG11201810627U A SG 11201810627UA
Authority
SG
Singapore
Prior art keywords
suite
international
hpv
seattle
methods
Prior art date
Application number
SG11201810627UA
Inventor
Frank Jones
Yvette Latchman
Adrian Rice
Elizabeth Gabitzsch
Joseph Balint
Original Assignee
Etubics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etubics Corp filed Critical Etubics Corp
Publication of SG11201810627UA publication Critical patent/SG11201810627UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) WIPO I PCT Iiiimmomiolollmolommoololoiolloiloomilioluovoiml (10) International Publication Number WO 2017/210649 Al (51) International Patent Classification: A61P 31/18 (2006.01) C12N 15/12 (2006.01) C07K 14/16 (2006.01) C12N 15/33 (2006.01) C07K 14/025 (2006.01) C12N 15/37 (2006.01) (21) International Application Number: PCT/US2017/035841 (22) International Filing Date: 02 June 2017 (02.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/345,592 03 June 2016 (03.06.2016) US (71) Applicant: ETUBICS CORPORATION [US/US]; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). (72) Inventors; and (71) Applicants: JONES, Frank, R. [US/US]; 410 West Harri- son Street, Suite 200, Seattle, WA 98119 (US). BALINT, Joseph [US/US]; 410 West Harrison Street, Suite 200, Seat- tle, WA 98119 (US). LATCHMAN, Yvette [US/US]; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). RICE, Adrian [US/US]; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). GABITZSCH, Elizabeth [US/US]; 410 West Harrison Street, Suite 200, Seattle, WA 98119 (US). (74) Agent: RAMANATHAN, Renuka et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — (54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED DISEASES 100 5 0 - co 2 O. - 0 - Ad5 [E1-E2b-]-null Ad5 [E1-E2b+ES/E7 0© 0 0 10 20 30 40 Days post tumor implantation FIG. 2B (57) : Methods and compositions for constructing and producing recombinant adenovirus- based vector vaccines are provided. In particular aspects, there are be provided compositions and methods involving adenovirus vectors comprising genes for target antigens, such as novel antigens of HPV E6 and/or HPV E7 for use in treatment methods that generate highly reactive anti-HPV and anti-tumor immune responses in subjects with preexisting immunity to adenovirus. [Continued on next page] W O 20 17 / 2106 49 Al WO 2017/210649 Al MIDEDIMOMMIDIROMEHIDEIONINHCHINVOIMIE Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201810627UA 2016-06-03 2017-06-02 Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases SG11201810627UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345592P 2016-06-03 2016-06-03
PCT/US2017/035841 WO2017210649A1 (en) 2016-06-03 2017-06-02 Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases

Publications (1)

Publication Number Publication Date
SG11201810627UA true SG11201810627UA (en) 2018-12-28

Family

ID=60477926

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810627UA SG11201810627UA (en) 2016-06-03 2017-06-02 Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases

Country Status (9)

Country Link
US (1) US20190134195A1 (en)
EP (1) EP3463577A4 (en)
JP (1) JP2019517522A (en)
KR (1) KR20190033483A (en)
CN (1) CN109862939A (en)
AU (1) AU2017272356A1 (en)
CA (1) CA3026360A1 (en)
SG (1) SG11201810627UA (en)
WO (1) WO2017210649A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042703A1 (en) * 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
CN110520436A (en) 2017-03-15 2019-11-29 潘迪恩治疗公司 Target immunological tolerance
JP2020521452A (en) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド Targeted tolerance
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3762022A4 (en) * 2018-03-06 2022-06-15 Precigen, Inc. Human papillomavirus vaccines and uses of the same
EP3773657A4 (en) * 2018-03-26 2021-12-08 Altor Bioscience LLC Anti-pdl1, il-15 and tgf-beta receptor combination molecules
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020231855A1 (en) 2019-05-10 2020-11-19 Nant Holdings Ip, Llc Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
BR112021023345A2 (en) 2019-05-20 2022-02-01 Pandion Operations Inc Targeted immunotolerance in madcam
US20220018844A1 (en) * 2020-07-20 2022-01-20 University Of Baltimore, Maryland Method for Treating a Cancer Based on Inflammatory Subtype Thereof
WO2022216984A1 (en) * 2021-04-08 2022-10-13 Board Of Regents, The University Of Texas System Methods and systems for hpv detection and quantification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
FR2794370B1 (en) * 1999-06-03 2003-10-17 Biovector Therapeutics POLYEPITOPIC PROTEIN FRAGMENTS, THEIR OBTAINMENT AND THEIR USES IN PARTICULAR IN VACCINATION
US20100061957A1 (en) * 2006-04-21 2010-03-11 Transgene S.A. Hpv-16-based papillomavirus vaccines
PL2118292T3 (en) * 2007-01-30 2011-12-30 Transgene Sa Papillomavirus e2 polypeptide used for vaccination
AU2009236585B2 (en) * 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CN102002105B (en) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Gene, expression vector, expression method, expression cell and application of human papilloma virus (HPV) 16 E7E6 fusion protein
EP2806889B1 (en) * 2012-01-24 2017-08-16 Sanford Health Polynucleotides for treating oncogenic viral polypeptide positive tumors
US9605276B2 (en) * 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US11352642B2 (en) * 2015-01-09 2022-06-07 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016172249A1 (en) * 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy

Also Published As

Publication number Publication date
WO2017210649A1 (en) 2017-12-07
CA3026360A1 (en) 2017-12-07
CN109862939A (en) 2019-06-07
EP3463577A1 (en) 2019-04-10
JP2019517522A (en) 2019-06-24
KR20190033483A (en) 2019-03-29
US20190134195A1 (en) 2019-05-09
WO2017210649A8 (en) 2018-01-25
EP3463577A4 (en) 2019-12-04
AU2017272356A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
SG11201810627UA (en) Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201811432WA (en) Rna for cancer therapy
SG11201810631SA (en) Compositions and methods for tumor vaccination using prostate cancer-associated antigens
SG11201810048VA (en) Tri-segmented pichinde viruses as vaccine vectors
SG11201900049QA (en) Crispr/cas9-based compositions and methods for treating retinal degenerations
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201900028VA (en) Crispr/cas9-based compositions and methods for treating cancer
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807003UA (en) Smc combination therapy for the treatment of cancer
SG11201906895WA (en) Rna cancer vaccines
SG11201808783XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201903407XA (en) Secretable variant immunomodulatory proteins and engineered cell therapy
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201809614VA (en) Method for the fabrication of three-dimensional objects and apparatus for same
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201808422QA (en) Gene therapy for treating hemophilia a
SG11201808457PA (en) Icos ligand variant immunomodulatory proteins and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201804836RA (en) Treatment of fibrosis